Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J5ED
|
|||
| Former ID |
DIB010544
|
|||
| Drug Name |
LTX-109
|
|||
| Synonyms |
Lytixar
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 2 | [1] | |
| Company |
Lytix Biopharma AS
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C43H69N11O3
|
|||
| Canonical SMILES |
CC(C)(C)C1=CC2=C(C(=C1)C(C)(C)C)NC(=C2CC(C(=O)NC(CCCN=C(N)N)C(=O)NCCC3=CC=CC=C3)NC(=O)C(CCCN=C(N)N)N)C(C)(C)C
|
|||
| InChI |
1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1
|
|||
| InChIKey |
ZVOYWSKEBVVLGW-ZDCRTTOTSA-N
|
|||
| CAS Number |
CAS 1166254-80-3
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:77752
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Cell membrane (Bact CM) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01223222) A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar (LTX-109) on Uncomplicated, Gram-positive, Skin Infection. U.S. National Institutes of Health. | |||
| REF 2 | A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.